The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2271-2272 December 4, 2003 Number 23
NextNext

Everolimus in Cardiac-Transplant Recipients

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Eisen, H. J.
-PubMed Citation
To the Editor: Eisen et al. (Aug. 28 issue)1 report less severe rejection and less intimal thickening in cardiac-transplant recipients who received everolimus than in those who received azathioprine. However, we are concerned about the marked and sustained impairment of renal function in patients treated with everolimus and full-dose cyclosporine; the mean creatinine concentration at the last measurement during treatment in the two everolimus groups was 2.15 mg per deciliter, as compared with 1.71 mg per deciliter in the azathioprine group, corresponding to a difference of approximately 11 ml per minute in estimated creatinine clearance. Renal impairment after cardiac transplantation . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.